Helius Medical Technologies, Inc. (NASDAQ:HSDT) is reporting third quarter financial results on Thursday 12th November 2020, after market close.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 2.00 million ~ $ 2.00 million
Click Here For More Historical Outlooks Of Helius Medical Technologies, Inc.
Previous Quarter Performance
Helius Medical Technologies, Inc. announced loss for the second quarter of $ 0.08 per share, from the revenue of $ 0.13 million.
Stock Performance
Shares of Helius Medical Technologies, Inc. traded up $ 0.02 or 3.75 percent on Wednesday, reaching $ 0.42 with volume of 122.10 thousand shares. Helius Medical Technologies, Inc. has traded high as $ 0.44 and has cracked $ 0.40 on the downward trend
The closing price of $ 0.42, representing a 64.00 % increase from the 52 week low of $ 0.25 and a 72.48 % decrease over the 52 week high of $ 1.49.
The company has a market capital of $ 22.36 million and is part of the Healthcare sector and Medical Devices industry.
Conference Call
Helius Medical Technologies, Inc. will be hosting a conference call at 5:45 PM eastern time on 12th November 2020, to discuss its 3Q20 financial results with the investment community. The participants may dial, 877-407-2988 (United States) or 201-389-0923 Toll Number, with passcode : 13711025 in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website heliusmedical.com
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, or acquiring noninvasive technologies for the treatment of symptoms caused by neurological disease or trauma. The companys product is Portable Neuromodulation Stimulator, a medical device in Canada for the treatment of chronic balance deficit associated with a mild to moderate traumatic brain injury. Its PoNS device treats neurostimulation of cranial nerves via the tongue to restore lost function.
